Genemarkers Sponsors Rare Disease Challenge
News May 02, 2013
Genemarkers will be providing Genomics Expression Analysis for Silveira’s research on Chronic Beryllium Disease (CBD). Silveira was selected out of 77 applicants covering 67 types of rare disease.
"We are thrilled to be part of the Rare Disease Challenge and to have the opportunity to assist Lori Silveira,” says Dr. Anna Langerveld, president and CEO of Genemarkers. “We are proud that our team of experienced genomics scientists can assist in advancing this research.”
Genemarkers joins 19 other companies as service donors for the competition, hosted by Assay Depot and Rare Genomics Institute. Rare Genomic Institute’s expert panel and a Genemarkers technical expert selected winners for the service donation. The total value of all services reached $500,000, which will go towards helping accelerate rare disease research. To view all service winners and company donations, please visit http://challenge.assaydepot.com/rare-disease-awards.
The competition also features a $10,000 prize with the winner being chosen by Facebook voting. The community can participate by voting for their favorite research proposals on Facebook at http://www.facebook.com/raregenomics.
Genemarkers will work with Lori Silveira over the next few months and push Chronic Beryllium Disease (CBD) research to a new level.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE
In a study of mice and human brain tumors researchers searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients’ tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation.READ MORE